Table 1

Baseline characteristics

Total populationN=53
Clinical features
 Age, median (IQR), years70 (66–76)
 Sex, male n (%)39 (74)
 BMI, median (IQR)25 (21–27)
 AF history,* n (%)6 (10)
 Hypertension, n (%)19 (36)
 Diabetes mellitus, n (%)6 (11)
 Coronary artery disease, n (%)2 (4)
 Valvular heart disease, n (%)0 (0)
 Heart failure history, n (%)2 (4)
 Pacemaker, n (%)1 (2)
 Smoking, n (%)14 (26)
 Obstructive sleep apnoea, n (%)0 (0)
 Thyroid disease, n (%)1 (2)
 Stroke history, n (%)2 (4)
 Major bleeding history, n (%)1 (2)
 CHADS2-VA2SC score, median (IQR)2 (1–3)
 HAS-BLED score, median (IQR)1 (1–2)
Antithrombotic therapy
 Antiplatelet therapy, n (%)7 (13)
 Anticoagulant therapy n (%)4 (8)
Malignancy
 CLL, n (%)38 (72)
 Waldenström disease, n (%)8 (15)
 Mantle lymphoma, n (%)4 (8)
 Marginal zone lymphoma, n (%)1 (2)
 Diffuse large B-cell lymphoma, n (%)2 (4)
Prior oncological treatment, n (%)51 (96)
Echocardiography
 LAVI, median (IQR), mL/m2 32 (28–40)
 LVEF, median (IQR), %61 (57–66)
 Global longitudinal strain† (%)19 (−21–−17)
  • *First diagnosed AF, n=1; paroxysmal AF, n=4; long-standing persistent AF, n=1.

  • †Values for n=47 patients.

  • AF, atrial fibrillation;BMI, body mass index;CLL, chronic lymphocytic leukaemia;LVAI, left atrial volume index;LVEF, left ventricular ejection fraction.